Target
- Clinical Innovation
- Business Development
- Investment Committee
The problem
Internal disease landscape analyses take 3 to 6 months, and still rarely meet the evidentiary standards an Investment Committee expects before committing to a new indication.
The solution
Comprehensive disease characterization and therapeutic landscape report in under three weeks: 12,000+ evidence sources assessed, 3,000+ articles extracted across peer-reviewed publications, registries, meta-analyses, and observational studies.
AI-powered extraction and synthesis of disease characteristics, safety and efficacy data, and client-specified research questions, answered directly within the deliverable.
Dual-format output, written study and fully structured, referenced dataset, ready for immediate use in Investment Committee presentations.
0% hallucination rate: every claim fully traceable to its original source, with quality control metrics provided alongside findings.
The impact
Biocodex's Clinical Innovation team received a complete disease and therapeutic landscape analysis in three weeks, enabling the Investment Committee to make a fully evidence-based go/no-go decision on a new therapeutic area.
Every claim verified, every source traceable.
“What convinced us was not just the speed of delivery, but the fact that every single claim was sourced and verifiable. That level of rigor is exactly what our Investment Committee expects.”